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Schizophrenia is considered a syndrome comprised by several disease phenotypes,
covering a range of underlying pathologies. One of these disease mechanisms seems
to involve immune dysregulation and neuroinflammation. While the current dopamine
receptor-blocking antipsychotic drugs decrease psychotic symptoms and prevent
relapse in the majority of patients with schizophrenia, there is a huge need to explore
new treatment options that target other pathophysiological pathways. Such studies
should aim at identifying robust biomarkers in order to diagnose and monitor the immune
biophenotype in schizophrenia and develop better selection procedures for clinical
trials with anti-inflammatory and immune-modulating drugs. In this focused review, we
describe available methods to assess inflammatory status and immune disturbances
in vivo. We also outline findings of immune disturbances and signs of inflammation at
cellular, protein, and brain imaging levels in patients with schizophrenia. Furthermore, we
summarize the results from studies with anti-inflammatory or other immune-modulating
drugs, highlighting how such studies have dealt with participant selection. Finally, we
propose a strategy to construct an immune signature that may be helpful in selecting and
monitoring participants in studies with immune modulating drugs and also applicable in
regular clinical work.
Keywords: CRP-C-reactive protein, schizophrenia, inflammation, immunity, cytokine, anti-inflammatory drugs,
monoclocal antibody, MRI
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INTRODUCTION
Immune dysregulation in schizophrenia has been found in
numerous studies comparing patients to healthy controls, and
meta-analyses find that patients with schizophrenia, on a group
level, show signs of a low-grade peripheral inflammation with
upregulation of several proinflammatory cytokines (1–3) and C-
reactive protein (CRP) (4). While the origin of these findings
is not established, a major result from genome wide association
studies (GWAS) has been a robust genetic association between
schizophrenia and the major histocompatibility complex (MCH)
locus on chromosome 6 (5). This genetic susceptibility can
in part be explained by variants of complement factor 4
(C4), possibly linked to increased synaptic pruning during
brain development (6). Furthermore, studies show increased
risk of schizophrenia in individuals with prenatal exposure to
influenza, although disputed (7), or with elevated titers of IgG
antibodies to toxoplasma gondii (8), likely to work in concert
with a genetic background (9). Interestingly, the pathological
influence of prenatal infection may be an unspecific effect
of having an inflammation response and increased cytokine
levels more than a specific effect of a particular infectional
agent (9). Moreover, studies of post-mortem brains of patients
with schizophrenia suggest increased microglial activity (10).
While these findings and others have broadened the knowledge
of how immunity may influence ethio-pathological processes
in schizophrenia, the advance of novel treatment algoritms
for the individual patient would benefit from identification of
robust immune-biomarkers for schizophrenia (11). In addition,
theranostic biomarkers predicting effects of treatment with anti-
inflammatory or immune-modulating drugs are needed (12)
and descriptive group level findings must be translated into
diagnostic assessment of the individual patient (11).
Although dopamine D2-receptor blocking antipsychotic
drugs play a major role in the treatment of psychotic disorders
(13), new treatment options are strongly needed, above all for
the cognitive and negative symptoms of schizophrenia. D2-
blockers offer symptomatic relief for delusions and hallucinations
and efficient relapse prevention to a majority of users
(14), but a disease-modifying effect in schizophrenia has
not been found. Immune-modulating treatments might target
pathological processes more proximal to the roots of the
psychotic disorder than is the case for the current D2-receptor
blocking drugs, and accordingly may be able to treat not only
symptoms. Since 2002, there has been several pivotal studies
exploring the potential effect of non-steroidal anti-inflammatory
drugs (NSAIDS) (15), estrogens, statins, EPA/DHA fatty acids,
davunetide, minocycline, and N-acetyl cysteine in schizophrenia
(16). Furthermore, trials with monoclonal antibodies toward
cytokines or cytokine receptors are emerging (17), which can
specifically target one component of the immune system and
may provide opportunities for precision medicine. This is a
rapidly developing field (18), that now contains a range of
well-established treatment options for various medical and
neurological disorders, such as multiple sclerosis (MS). There
is now a broad understanding that immune dysregulation may
form an important part of the pathophysiology of schizophrenia
and a whole range of drugs targeting specific parts of the immune
system are already available. Following up on the studies with
various anti-inflammatory acting drugs that have already been
conducted, the stage is set for a new phase of drug studies in
schizophrenia (19).
However, in order to maximize chances of showing effect
in studies with immune-modulating drugs a schizophrenia
inflammatory phenotype should be defined and delineated at the
individual level both for research and clinical purposes. Several
authors have highlighted that in most studies of inflammation in
schizophrenia around 40% of the patients have some degree of
inflammation (20–22). Assuming that immune dysregulation is
involved in the pathoetiology of sub-groups with schizophrenia
is in line with the notion that schizophrenia is a syndrome
comprised by several disease phenotypes with a range of distinct
underlying pathologies (23, 24). One of these diseasemechanisms
could be related to immunity, while others may be more
influenced by compromised energy metabolism or synaptic
dysfunctions (11). As several authors have noted already, we
need robust biomarkers to diagnose immune dysregulation in
schizophrenia and help selecting participants for trials with
immune-modulating drugs. Further down the line, biomarkers
are also needed in clinical settings in order to evaluate the
individual patient for treatment. Promising indications of the
possibilities that such a strategy represents derive from trials
with immune-modulating drugs in depression. In two studies
of infliximab which blocks tumor necrosis factor (TNF)-α
in patients with major depression, treatment only benefited
participants with CRP above a certain level (25, 26). Also, a
schizophrenia trial stratifying results on degree of inflammation
showed stronger treatment effects in the participants with
increased inflammation (27).
Here we first review available methods to assess inflammatory
status or immune disturbances. Findings of disturbances in
immune cells, cytokines including mRNA, acute phase proteins,
other molecular level methods and findings, and brain imaging
methods will be outlined. Furthermore, we summarize the
results from studies with anti-inflammatory or other immune-
modulating drugs, highlighting how the studies have dealt with
participant selection. Finally, we propose a strategy to construct
an inflammatory signature that may be useful in selecting and
monitoring participants in studies with immune modulating
drugs and also applicable in the regular clinical work. We will
start with a brief overview of the immune system.
IMMUNITY AND INFLAMMATION
The two categorically different parts of the immune systems are
the innate system—that responds to pathogens in an unspecific
way but does not produce lasting immunity—and the adaptive
system which responds to specific antigens in a way that
creates long-lasting recognition. The long-lasting recognition is
produced through the creation of cell lines that give a specific
antibody response. The cells of the innate system are the dendritic
cells (DC), the macrophages, granulocytes, mast cells, and the
natural killer (NK) cells, while the humoral responses of the
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FIGURE 1 | The immune system—an overview.
innate system consist of the complement system, cytokines and
interferons. The cells of the adaptive system are the B and T
lymphocytes, while the antibodies are the humoral part of the
adaptive system (28), see Figure 1. An important part of the
innate response is the toll-like receptors (TLRs) located at the
macrophages where they induce phagocytosis and production of
albumin, fibrinogen, and serum amyloid A protein together with
CRP—the acute phase proteins (29). A further acute response
consists of the production of cytokines that stimulates T and
B cells into producing responses specific to the given antigen.
T cells are divided into subsets on the basis of their surface
receptors, and the twomain types are the cluster of differentiation
(CD)4 T helper(h) cell, and the CD8—the T killer cells. The
CD4 Th cells secrete a major portion of the cytokines of
the body. Cytokines and chemokines are small molecules that
act predominantly in the microenvironment of the cells that
secrete them, while interleukin (IL)-1β, transforming growth
factor (TGF) and TNF are exceptions to this and can also
circulate through the body (28). Cytokines and chemokines
have important roles in the communication between cells in the
immune system, they can have stimulatory or inhibitory effects
and their role may change depending on context. When the
CD4 Th cell is activated, it can differentiate into Th1 and Th2
effector cells producing different types of cytokines. Th1 cells
produce interferon (IFN)- γ which has strong pro-inflammatory
properties, while the Th2 cells upon stimulation produces IL-4,
IL-5, IL-10, IL-13 with mixed effects (30). CD4 Th cells can also
differentiate into Th17 cells and induced regulatory T (iTreg)
cells. Th17 produces several cytokines with a predominantly pro-
inflammatory effect, IL-17, IL-23, IL-21, IL-22, and IL-17/IL-23
induce the IL-17/IL-23 immune axis (31).
Several specific cytokines need particular attention as they are
consistently reported to be associated with schizophrenia. The
IL-1 family consists of seven proteins displaying a predominantly
pro-inflammmatory function: IL-1α, IL-1β, IL-18, IL-33, IL-
36a, IL-36b, IL-36g, moreover three receptor antagonists IL-
1Ra, IL-36Ra, IL-38, and one cytokine with anti-inflammatory
actions; IL-37 (32). The IL-1 family are pleiotropic, and also
have immunoregulatory and hematopoitic effects (28). IL-1
influences antigen presentation and non-specific lymphocyte
function, and is closely linked to innate immunity (33). The
IL-1 receptor type 1(RI) shows strong similarities to the TLR.
Binding of IL-1 can initiate and strengthen the acute phase
response by inducing fever that increases migration of leucocytes,
by stimulating the acute phase proteins such as CRP, by
activation of the hypothalamus-pituitary-adrenal (HPA) axis
with cortisol regulating innate inflammation, and by inducing
adhesion molecules that increase leucocyte recruitement (32).
IL1 is mainly produced by activated macrophages, which is
for instance activated by interferon (IFN)-γ and bacterial
products (28, 32). IL-6 is produced by immune cells, adipocytes,
skeletal muscle cells and vascular endothelial cells, and the IL-
6 receptor is located on macrophages, lymphocytes, neutrophils
and hepatocytes (34). IL-6 stimulates B cell differentation and
activation of T cells in acute inflammation, and promotes the
synthesis of CRP, fibrinogen and albumin in the acute response
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(34). IL-6 influences the aforementioned differentiation of Th17
cells together with TGF-β, and constrains TGF-induced Treg cells
differentiation (35). The fatigue, anorexia and fever associated
with acute inflammations may be induced by IL-6 (36). However,
IL6 also has a role in dampening the inflammatory response
by reducing the production of IL-1β and TNF-α (37), and
by inducing the production of IL-1 Ra (38) and the anti-
inflammatory cytokine IL-10 (39). Recent results indicate that
activation of IL-6 without a concomitant activation of IL-1β and
TNF, for example during physical exercise, mostly induces anti-
inflammatory actions (39). TNF-α is another pro-inflammatory
cytokine with important functions in innate and adaptive
immunity. It is produced in macrophages and monocytes, as
well as in T-cells, adipocytes and smooth muscle cells and binds
to tumor necrosis factor receptor type I (TNF-RI) and type
II (TNF-RII). With the exception of erythrocytes, TNF-RI and
TNF-RII are located on all cells of the body and are involved
in pro-inflammatory pathways through the activation of nuclear
factor-kB (40).
DYSREGULATED IMMUNE SYSTEM AND
INFLAMMATION IN SCHIZOPHRENIA
There is a growing body of evidence implicating dysregulated
immunity in schizophrenia from both in-vitro and in-vivo
studies. In this overview we will limit the description to
studies applying tissues and methods that can potentially
become useful in the clinical assessments of patients. We
will present relevant immune cells, cytokines and acute phase
proteins, expression of cytokine genes, other proteins and
metabolites, and finally brain imaging methods used to assess
neuroinflammation, see Figure 2.
Assessments in Peripheral Tissues
Immune Cells
The immune cells are the cornerstones of the immune system,
and it is rather unlikely that an immune disturbance of possible
pathoetiological significance in schizophrenia would be present
without a detectable immune cell signature. However, few studies
have described immune cell disturbances so far. A meta-analysis
of 16 studies of lymphocytes in schizophrenia vs. healthy controls
(41) showed a significant increase in the percentage of CD4
and CD56 (natural killer cells) in acutely ill patients. Drug
naïve first episode patients showed a significant increase in the
levels of lymphocytes, CD3 (all T-cells) and CD4 levels, and
the CD4/CD8 ratio. Absolute CD56 levels were suggested to be
trait-dependent, while CD4/CD8 ratio could be state-dependent.
A study of 18 patients with schizophrenia (17 treated with
clozapine) vs. 18 healthy persons found elevated monocytes,
NK cells, naïve B cells and CXCR5+ memory CD4 cells in the
schizophrenia group, and decreased number of DC and several
T cells populations. The authors find it plausible that clozapine
treatment influenced the results (42). In a selective review by
Bergink et al. (43) several studies report elevated monocyte
counts in the periphery of patients with schizophrenia and
higher gene expression for inflammatory cytokines in circulating
monocytes. For circulating T cells three referred studies found
reduced numbers of circulating lymphocytes, while one study
found increased numbers of Th1, Th17, and suppressive natural
T regulatory cells (44). In a study of 69 drug-naïve first episode
patients with schizophrenia (FES) compared to 70 healthy
controls, FES had significantly higher proportion of Th17 cells
(45), and the proportion of Th17 cells correlated positively
with PANSS total. Interestingly, after 4 weeks of treatment with
risperidone, the proportion of Th17 cells decreased significantly.
However, conflicting results regarding the Th17 axis have been
published (30). It is clearly an advantage from a clinical point
of view that immune cells can be assessed with well-established
and readily available methods, for example flow-cytometry (46),
and are routinely surveyed in the clinical treatment of various
conditions, see for example the website of the Karolinska hospital
where a full menu of lymphocyte immunphenotyping is offered
(www.karolinska.se). Taken together, studies of lymphocytes
as well as monocytes in patients with schizophrenia show
very interesting differences compared to healthy controls,
but more research is needed to evaluate immune cell counts
such as lymphocyte immunophenotyping as theranostic
biomarkers for immune dysregulation/inflammation in
schizophrenia.
Cytokine Protein Levels in Serum
A major body of knowledge regarding immune dysfunction in
schizophrenia derives from studies on cytokines in peripheral
blood. During the last two decades, many studies have been
performed and new ones are arriving (47). Others have
summarized these results in systematic reviews and meta-
analyses (1–3). The recent study by Rodrigues-Amorim et al. (3)
also contains a very helpful summary of the function and clinical
impact of the different cytokines. They included 99 studies
with 8,234 participants and found that peripheral levels of the
following cytokines differed between patients with schizophrenia
and healthy controls in more than 50% of the included studies,
listed according to falling prevalence among the studies: IL-6,
TNF-α, IL-10, IFN-γ, IL-1β, IL-8, IL-2, IL-1RA, furthermore the
gene polymorphisms for TNF-α 1800629, IL-6 rs1800795, and
IL-1β rs16944, and elevated expression levels of IL-6, TNFR1,
TNFR2, and IL-1β mRNAs (3). It is important to emphasize that
the identified changes are smaller in magnitude compared to
findings from for example inflammation in rheumatoid artritis
and other auto-immune disorders, and collectively it is referred
to as a low-grade inflammation (48).
Drug-naïve FES
IL-1β, soluble (s)IL-2receptor(R), IL-6, and TNF-α were
significantly elevated in a meta-analysis of 23 studies with 570
subjects with drug-naïve FES vs. 683 controls (1). Also non-
significant changes of IL-2, IL-4, and IFN-γ were identified. An
earlier meta-analysis with 14 studies in FES (2) found IL-1β,
sIL-2R, IL-6, IL-12, TNF-α, IFN-γ, TGF-β to be increased in
FES vs. controls. Furthermore, in a study of 12 ultra-high risk
(UHR) individuals compared to 16 healthy controls IL-17 was
significantly decreased and IL-6 increased in the UHR group
(49). The finding of low-grade peripheral inflammation in a
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FIGURE 2 | Putative components comprising the immune signature in schizophrenia. BBB, blood-brain-barrier; CSF, cerebrospinal fluid; TSPO, translocator protein;
VEGF, vascular endothelial growth factor; IL, interleukin; IFN, interferon; RA, receptor antibody; R, receptor; TGF, transforming growth factor; TNF, tumor necrosis
factor; MMP, matrix metalloproteinase; ACE, angiotensine converting enzyme; TBG, thyroxine-binding globuline; TSH, thyrioidea stimulating hormone; ICAM,
intercellular adhesion molecule; PUFAs, poly-unsaturated fatty acids; NMDA, N-methyl-D-aspartate.
subset of drug-naïve patients at the time of diagnosis is among
the stronger underpinnings of the “inflammation hypothesis” in
schizophrenia. However, as a general Th1/Th2 imbalance is not
found the interpretation of the findings in terms of underlying
immune disturbances is not clear (1).
Effects of antipsychotic treatment on cytokine levels
In a meta-analysis including 8 studies of drug-naïve patients
with first-episode psychosis (FEP) a significant reduction after
antipsychotic treatment for IL-2 and IL-6 was found. After
excluding only one study IL-1β also declined significantly (50).
The authors suggested that IL-1β, IL-2, and IL-6 could serve
as markers for psychosis, while TNF-α, IL-17, and IFN-γ
were still elevated after antipsychotic treatment. The analyses
included in total between 69 (IL-2) and 253 (IL-6) subjects,
and included studies with data available after 4 weeks of
antipsychotic treatment. An earlier review of cytokine changes
after antipsychotic treatment (4 to 52 weeks) including 39 studies
with schizophrenia spectrum patients found that antipsychotic
treatment was associated with reduced IL-2, increased sIL-2R and
sTNF-R1/R2 and in some studies also an increase in IL-4 (51).
Another meta-analysis found that sIL-2R and IL-12 increased
and IL-1β, IL-2, and IL-6 decreased with antipsychotic treatment
after a mean period of 53 days with antipsychotic treatment (2)
including studies with both first-episode and chronic patients.
The most consistent finding is a reduction in IL-2 and/or
increase in sIL-2R. IL-2 is primarily secreted from activated T-
lymphocytes, and is an immunoregulator stimulating growth and
development of immune cells in peripheral tissue early in the
immune response, and the growth of oligodendrocytes in neural
tissue (28). Accordingly, the reduction of IL-2 after antipsychotic
treatment implies a decreased immune response.
Deficit syndrome—negative symptoms
A study in patients with the deficit syndrome of schizophrenia—
a subgroup of patients with primary negative symptoms from
the illness debut—found significantly elevated IL-6 and TNF-
α in patients with deficit syndrome compared to in non-deficit
schizophrenia and healthy controls (52). The association between
negative symptoms and elevated specific cytokines is particularly
interesting as antipsychotics are not effective treatment options
for negative symptoms. Drug trials with immunomodulating
agents targeting negative symptoms are specificly warranted.
A recent meta-analysis by Goldsmith et al. (53) summarized
existing findings regarding cytokine alterations in schizophrenia,
bipolar disorder and major depressive disorder (MDD), and also
compared results from acute and chronic phases. IL-6, TNF-
α, IL-1RA, and sIL-2R were all elevated in the acute phases
of all three disorders. After treatment, IL-6 decreased both in
schizophrenia andMDD, while TNF-α did not change. In chronic
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states, IL-6 was elevated in all three disorders, while IL-1β and
sIL-2R were elevated in schizophrenia and bipolar disorder. The
authors conclude that there is a distinct similarity between the
acute phases across all three diagnoses and they highlight that
the cytokines with elevated levels in the three disorders are all
modulated by nuclear factor-κB, regularly found to be activated
in autoimmune and inflammatory disorders (53).
Some of the pro-inflammatory cytokines can barely be
measured in healthy persons, while in infection-associated
inflammatory responses, the concentrations rise 10 to 100-
fold. In addition multiple confounders such as age, gender,
smoking, body mass index (BMI), and diurnal variation may
influence the results (2). Further, cytokine activity is inter-
dependent with the hypothalamic pituitary adrenal axis. As a
first psychotic episode generally induces high stress levels, it
is unclear whether the observed cytokine rises are a general
stress phenomenon, or a specific signature of psychosis. Finally,
schizophrenia patients face a high burden of co-morbidity in
terms of cardiometabolic disorders. As inflammation also plays
a central role in the pathophysiology underlying these diseases,
future research should address the nature of this relationship.
Altered cytokine levels associated with schizophrenia could either
be the result or cause of co-morbid disease, or there could
be common immunopathogenetic mechanisms underlying both
schizophrenia and for instance cardiovascular disease.
Having mentioned these problematic dimensions of cytokine
measurement, the pro-inflammatory cytokines IL-1β, IL-6, and
TNF-α seem to covariate with psychosis and could be useful
tools for selecting participants to drug-studies with immune-
modulating drugs targeting for example positive symptoms of
schizophrenia.
Cytokine mRNA Levels
A study reporting differences in gene expression between
529 patients with schizophrenia and 660 healthy controls
found 1,058 differentially expressed genes, of which 697
genes were upregulated (54). Gene set enrichment analysis
showed that the upregulated genes were enriched in several
processes involved in the response, activation and regulation of
immunity. Differentially expressed immune genes included four
complement genes: CR1, CR2, CD55, and C3, as well as TGFβ1
and TGM2. A study with combined measurement of mRNAs of
cytokines and peripheral cytokines in plasma and serum aimed to
define an inflammatory biotype of schizophrenia (20). This study
used a recursive two-step cluster analysis to define subgroups of
pro-inflammatory status on the basis of mRNAs of IL-18, IL-
1β, IL-6, and IL-8. The cluster analysis included 68 controls and
82 patients. The results identified three clusters, cluster 1—low
cytokine expression (n = 89), with below median expression of
all measured cytokine mRNAs, cluster 2 (n = 50) was termed
high cytokine expression and had above median for two and
above third quartile for two cytokine mRNAs, while the very
high cytokine expression group (n = 11) of cluster 3 were above
the third quartile for all four cytokine mRNAs. 47.6% in the
schizophrenia group was either cluster two or three compared
to 32.4% in the healthy control group. The elevated/non-
elevated subgroups of the schizophrenia participants did not
differ with respect to gender, BMI, duration of illness or
symptom severity as measured by the PANSS. Interestingly, the
authors discussed the limited correlation between peripheral
cytokine proteins and their mRNAs, and suggested that the main
source of cytokine proteins may not be peripheral leucocytes.
Furthermore, they suggested that mRNAs of pro-inflammatory
cytokines could be used to select the patients who have an
“elevated inflammation biotype” (20). In a study comparing 53
patients with schizophrenia and 53 healthy controls intracellular
levels of IL-6 mRNA in the peripheral blood mononuclear cells
(PBMC) analyzed with quantitative real-time polymerase chain
reaction (RT-PCR) was found to be significantly elevated for
patients with schizophrenia (55), and PBMC IL-6 mRNA was
specifically suggested to be a candidate for a diagnostic marker
for schizophrenia (55).
Acute Phase Proteins
CRP is an acute phase protein produced in the liver, stimulated
by IL-1β, IL-6, and TNF (56) and released by macrophages
and adipocytes. As demonstrated in the 2013 Guideline on the
Assessment of Cardiovascular Risk from the American College of
Cardiology and the American Heart Association (57) where CRP
is now recommended as a supplementary test using a threshold
of CRP ≥ 2 to indicate increased cardiovascular risk, CRP is
widely used in clinical practice as a marker of inflammation.
Another major advantage of CRP is that it can be measured
reliably in most certified laboratories. A recent meta-analysis
of 18 studies with 1,963 patients and 3,683 non-schizophrenia
controls found that a diagnosis of schizophrenia was associated
with a moderate increase in blood CRP (58), corroborating the
results of a prior meta-analysis (4). Furthermore, patients from
Asia or Africa and those who were younger than 30 years had
higher CRP levels. The increase in CRP correlated with positive
symptoms of schizophrenia but was unresponsive to initiation of
antipsychotic treatment (4). A large and recent study (n > 1,000)
reported elevated levels of CRP in patients with schizophrenia
compared to controls, with levels of CRP correlating both to
positive and negative symptoms (59). There is also evidence
indicating a relationship between CRP and cognitive dysfunction
in subjects with psychosis (60). In a recent systematic review
by Orsolini et al. (61) elevated CRP levels were again identified
in patients with schizophrenia and correlating with severity of
symptoms. Interestingly, a large genome wide association study
(GWAS) using mendelian randomization found that genetic
factors that elevate CRP have a preventive effect with respect
to developing schizophrenia (62), and the authors discussed
that increased CRP in schizophrenia is more likely a result of
developing and having the disease than being a predisposing
factor. Various psychiatric disorders were investigated in a study
assessing CRP in 599 admissions in a psychiatric catchment
area. The prevalence of inflammation defined as CRP > 3 mg/L
was 32% for psychotic disorders (ICD F 20–29), 21% for mood
disorders (F30–39), 22% for neurotic disorders (F 40–48), and
42% for personality disorders (F60–69), indicating that low grade
inflammation could be present in a whole range of psychiatric
disorders (21). As obesity is more common among patients
with a psychiatric diagnosis, the increase in adipose tissue and
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resulting higher risk for diabetes type 2 and cardiovascular
illness could be an intermediating factor (63). Yet, even after
adjusting for BMI CRP levels remain higher in patients (64).
Furthermore, in a study of patients with first admissions to
hospital with diagnoses of schizophrenia, bipolar disorders or
depression, survival-analyses showed that moderately elevated
CRP (3–10 mg/L) was associated with an increase in all-cause
mortality with adjusted hazard rate (HR) of 1.56 (95% CI: 1.02–
2.38), and for levels above 10 mg/L the adjusted HR was 2.07
(95% CI: 1.30–3.29). To conclude, the acute phase protein CRP
is elevated in a proportion of individuals with schizophrenia and
other psychoses, the measure is reliable and widely available,
and it has been found to correlate both with positive symptoms
of schizophrenia and cognitive function. Expression profiles of
the additional acute phase proteins—haptoglobin (HP), alpha-
1 antitrypsin (A1T), and alpha-2 macroglobulin (A2M) were
investigated with quantitative polymerase chain reaction (qPCR)
in a sample with 43 FEP patients and 57 healthy controls followed
up for 3 months (65). All three acute phase proteins were elevated
during the study period, and correlated with PANSS positive,
depressive, and excitement subscales. The results are in line with
previous studies using proteomic techniques identifying changes
in acute phase proteins in patients with schizophrenia supporting
that inflammation is an important feature in schizophrenia
(66, 67).
Additional Circulating Proteins and Metabolites
Related to Inflammation
Several methods with the capacity to identify and quantify
several hundreds to thousand molecules simultaneously have
been used to analyse blood sera from patients with schizophrenia.
These techniques are referred to as proteomics using multiplex
immunoassay, two-dimensional gel electrophoresis and mass
spectrometry for identifying proteins, and metabolomics using
metabolomics mass spectrometry and 1H-nuclear magnetic
resonance spectroscopy (MRS) for identifying smaller circulating
metabolites (68). Using proteomics, one interesting study
comparing 17 drug-naïve FES to 17 healthy controls found that
9 proteins (creatine kinase m/B, MMP3, ACE, cortisol, TBG, α-
2 macroblobulin, thrombopoietin, TSH, and ICAM-1) displayed
lower concentrations in the patients vs. the controls (69). The
authors commented that most of these proteins are involved
in endothelial cell function and inflammation. Another study
recently reported results from a novel proteomic method on
PBMC from 20 patients with schizophrenia assessed both while
acutely ill and in the recovery phase and compared to healthy
controls. Interestingly, the study found significant differences
in α-defencins 1–3 between the acutely admitted patients
and healthy controls (70). A systematic review of metabolite
biomarkers of schizophrenia that included 63 studies discussed
their findings of decreased levels of the antioxidant vitamin
E, polyunsaturated fatty acids (PUFAs), and phospholipids
together with high levels of lipid peroxidation metabolites
to indicate an oxidative balance favoring pro-oxidants and
thus also inflammation in patients with schizophrenia (71).
Although proteomics or metabolomics have not yet been applied
as tools in treatment guidance for individual patients with
schizophrenia, some have suggested how the use of these
methods could improve treatment (11, 72). As recently proposed
for mood disorders, using immune-based biomarkers together
with traditional clinical descriptions of the individual patients
may potentially improve both drug studies and individual
treatment (73). Schwarz et al. (74) used proteomics to divide
patients with schizophrenia into three groups: those with
immune signature, those with growth factor disturbances and
those with hormonal abnormalities. Such subdivisions could
help to identify patient groups for specific augmentation
therapy, for example with components such as NSAIDs,
metformin or selective estrogen receptor modulators. Future
drug trials should implement the promising results from this
rapidly developing field in order to enable and provide time-
efficient and personalized treatment options approaches. By
combining several proteomic/metabolomic markers indicating
inflammation in patients with schizophrenia, these methods
could offer specific and sensitive ways to select participants
for drug trials and monitoring drug effects on the molecular
level (72).
Antibodies
Elevation of some antibody-titers has been linked to
schizophrenia. A systematic quantitative review including
81 studies, showed that increased anticardiolipin IgG and
N-methyl-D-aspartate (NMDA) receptor autoantibody titers
and several additional autoantibodies were more prevalent in
patients with schizophrenia (75). In contrast, another study
of three cohorts of patients with schizophrenia stated that
peripheral NMDA receptor autoantibodies are very rare in
patients with schizophrenia (76). Also antibodies to gliadin
have been found elevated in studies comparing patients with
schizophrenia to healthy controls, but this was not the case
for antibodies more specific to coeliac disease (77). While the
recognition and early treatment of auto-immune encephalitis is
an important part in the differential diagnosis of schizophrenia,
it is unclear if the presence of auto-antibodies in serum without
specific symptoms of auto-immune encephalitis (convulsions,
rapid progression, decreased consciousness, and stereotypic
movements) warrant additional treatment (78). Although of
considerable interest, the origin and effect of these findings
in patients with schizophrenia are not yet clear, and their
usefulness in the mapping of inflammation in schizophrenia is
elusive.
Blood Brain Barrier Hyperpermeability
Evidence indicate increased permeability in the blood brain
barrier (BBB) in a subset of patients with schizophrenia (79).
One study found that 14 out of 39 patients with schizophrenia
spectrum disorders displayed signs of BBB hyperpermeability
including 9 patients with increased albumin cerebrospinal fluid
(CSF)/serum concentration quotient (80). A recent meta-analysis
by Orlovska-Waast et al. (81) with 32 studies concluded that
patients with bipolar disorder and schizophrenia may display
BBB abnormalities, but the authors also noted that the quality of
available studies is rather low. Increased levels of S100B protein
in blood and CSF that can be caused by BBB hyperpermeability
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(82) and elevated vascular endothelial growth factor (VEGF), a
protein known to increase BBB permeability, have been found
in patients with schizophrenia (83). Also increased levels of
vascular endothelial adhesion molecules and integrin receptor
have been detected in schizophrenia (84). A PET study focusing
on P-glycoprotein (P-gp), a major efflux pump in the BBB,
found it to be more active in schizophrenia (85) but this finding
needs to be replicated. Increased BBB permeability can have
deleterious effects on the brain by pro-inflammatory cells and
molecules entering in brain (79). Although, there is no concensus
regarding the best way to monitor increased BBB permeability in
patients with schizophrenia, several novel candidates including
matrix metalloproteinase-9(MMP-9), ubiquitin carboxy-
terminal hydrolase-L1(UCHL-L1), neurofilaments, brain derived
neurotropic factor (BDNF), miRNA in addition to S100B and
glial fibrillary acidic protein (GFAP) are available for future
studies, and preferably aggregated and applied in panels of
several biomarkers (86).
Assessments in the Brain
Neuroinflammation and Positron Emission
Tomography (PET)
The concept of neuroinflammation indicates innate immune
responses in the central nervous system (CNS) mainly produced
by microglia and astrocytes (87), in contrast to the term
neuroimmunology that denotes adaptive immunological
changes within the CNS (88). However, the use of the term
neuroinflammation to describe low-grade changes associated
with depression and schizophrenia is controversial. One
study that examined gene expression in brain in well-
established inflammatory diseases (inflammatory bowel
disease, juvenile dermatomyositis, MS, and ulcerative colitis)
compared to the neurodevelopmental/neurodegenerative
diseases Alzheimers disease, Parkinsons disease and
schizophrenia reported a categorical difference between the
neurodevelopmental/neurodegenerative diseases and the
inflammatory diseases (89). The authors state that a distinction
between classical neuroinflammatory conditions such as MS with
typical mononuclear infiltrates and the smaller and ill-defined
glial changes associated with secretion of various immune
molecules must be established, and that missing this point may
lead to unwarranted treatment trials (89). Nevertheless, classical
neuroinflammation or more precisely microglial activation has
been demonstrated to correlate with microglial expression of
the translocator protein (TSPO) which is located at the outer
mitochondrial membrane (90). While early studies with first
generation TSPO PET tracers, for example [11C](R)-(1-[2-
chrorophynyl]-N-methyl-N-[1-methylpropyl]-3 isoquinoline
carboxamide (11C-(R)-PK11195) showed increased TSPO
binding (91, 92), more recent studies did not find signs of
microglial activation using the PK11195 tracer (93), and the
specificity of TSPO binding to assess the inflammation associated
with schizophrenia has been challenged (94). Second generation
TSPO tracers have been developed, and in some studies increased
microglial TSPO expression between patients with schizophrenia
and healthy controls have been observed (95), while other did
not find signs of increased TSPO expression (96). A recent meta-
analysis that reviewed five studies with 75 patients and 77 healthy
controls found that patients with schizophrenia had lower TSPO
binding compared to controls, and concluded that this difference
is caused either by lower density or altered function of brain
immune cells (97). Hence, the advantage of measuring TSPO
binding to assess low-grade inflammatory changes associated
with schizophrenia seems to be in question, and the usefulness of
the method to select patients with an “inflammatory” phenotype
and monitoring effect of anti-inflammatory drugs appears to be
low.
Magnetic Resonance Imaging (MRI) and Magnetic
Resonance Spectroscopy (MRS)
MRI and MRS have also been proposed as potential means to
measure the low-grade inflammatory changes associated with
schizophrenia (98). MRS can measure concentrations of various
molecules in defined volumes of the brain. Increased levels of glial
markers as myo-inositol (MI), cholin (Cho) and total creatin,
and reduced levels of neuronal markers as N-acetylaspartate and
glutamate have been interpreted to indicate various dimensions
of inflammation, such as increased density of glial cells and
migration of glial cells into the inflamed area (98). MRS has
so far been used in few studies to assess inflammation in
schizophrenia. One study scanned 60 drug-naïve FES patients
and 60 controls. The results showed elevated MI, Cho, and
glutamate in the FES group (99) and were presented as evidence
of inflammation in the early phase of schizophrenia. Also
results from T1- and T2- weighted structural MRI and diffusion
MRI free-water imaging may be used to assess low-scale brain
inflammation (98, 100). The free-water imaging measures the
amount of extracellular water in brain tissue and is postulated
to correlate with oedema and possibly inflammation, and a
few studies have identified increased free-water in samples of
patients with schizophrenia compared to controls (101, 102).
Taken together, MR based tecniques pose exciting opportunities
to assess the subtle brain changes associated with schizophrenia.
However, more research is needed to understand the relationship
between these changes and other measures of inflammation, for
example cytokine levels in CSF and the peripheral circulation,
before they can be applied as markers of inflammation in
the individual patient with schizophrenia. Prasad et al. found
associations between diffusion tensor imaging measures and
the levels of IL6 and CRP (103), but we have not identified
studies exploring the relationship between more novel MRI
methods and markers of inflammation in CSF or peripheral
blood.
Cytokines in the Cerebrospinal Fluid
A meta-analysis including 16 studies comparing schizophrenia
with healthy controls, found increased CSF levels of IL-1β,
IL-6, IL-8, kynurenine, and kynurenic acid, while sIL-2R was
decreased (104). With the exception of sIL-2R, increased levels
of the same cytokines (IL-1β, IL-6, IL-8) have been reported
in the periphery (2). A recent meta-analysis that included
32 studies also found that IL-6 and IL-8 were significantly
elevated in schizophrenia (81). Presently it is not obvious that
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assessment of markers of inflammation in CSF to diagnose an
inflammatory biotype in individual patients with schizophrenia
will give additional gain vs. assessments in peripheral blood.
With the exception of some countries, for example Germany and
Denmark that investigate liquor in first episode patients to screen
for Lyme’s disease and other infectious causes, CSF assessment
is not part of clinical practice for patients with psychosis. On
the other hand, studies investigating CSF in schizophrenia are
scarce and the number of participants are small compared
to studies using peripheral measurements and future research
might prove measuring inflammatory markers in CSF to be
useful.
DRUG STUDIES TO TREAT IMMUNE




Anti-inflammatory drugs have been used as add-on to
antipsychotic treatment in patients with schizophrenia,
with some success–see Table 1. The results are summarized
in several meta-analyses: Sommer et al. included 4 studies
with celecoxib, one with acetylsalicylic acid/aspirin (117), and
reviewed 5 studies with celecoxib and 2 with aspirin in their
broader meta-analysis of anti-inflammatory agents (16). A
significant beneficial effect on PANSS total score of treatment
with aspirin was found. As already mentioned, one randomized
controlled trial (RCT) with aspirin showed stronger effects when
stratifying participants on the basis of a marker of inflammation
(27). Nitta et al. included 7 studies with celecoxib and 2 with
aspirin (105). NSAIDS significantly reduced PANSS positive
symptoms. The effects were moderated by aspirin treatment,
in-patient treatment, first episode patients and lower PANSS
negative scores. Zheng et al. conducted a meta-analysis including
8 studies with celecoxib conducted between 2002 and 2010, most
of them were also included in the previously published meta-
analyses (106). They concluded that treatment with celecoxib
outperformed placebo in studies of first-episode patients, but not
in patients with chronic schizophrenia. Effects were moderated
by higher positive symptoms and lower negative symptoms at
baseline. A few RCTs with anti-inflammatory drugs as add-on
to antipsychotic treatment have been published after these
overviews. Weiser et al. published a conference paper where
they reanalyzed an RCT where patients with schizophrenia were
randomized to treatment with either aspirine, minocycline,
the dopamine-agonist pramipexole, or placebo (118). After
subgrouping the participants according to CRP levels, they
showed that in the upper third group with CRP above 3.8 mg/L,
aspirine had a significant effect on PANSS positive symptoms.
However, this was not found for other symptom measures, and
not for participants treated with minocycline or pramipexole.
Steroidal Anti-inflammatory Drugs
Prednisolone, a synthetic corticosteroid, has been used for
several decades in the treatment of various inflammatory and
autoimmune disorders (119). The agent is more potent than
NSAIDS as it targets several aspects of the immune system
and interferes with almost all types of immune cells (120).
Furthermore, prednisolone readily crosses the BBB. There are
currently two recruiting randomized, placebo-controlled add-on
trials investigating prednisolone in early phase schizophrena and
related disorders (ClinicalTrials.gov Identifiers NCT03340909
and NCT02949232).
Novel Biological Drugs With
Immune-Modulating Actions
The availability of monoclonal antibodies toward cytokines,
cytokine receptors or other specific parts of the immune
system, in combination with findings of elevated cytokine levels
in schizophrenia imply that studies with these drugs would
strongly enhance our knowledge about cytokine dysfunction
in schizophrenia. Drawing upon the experience with targeted
immune therapy in diseases such as rheumatoid arthritis,
psoriasis, Chrohns disease, ulcerative colitis, spondyloarthritis,
and systemic lupus erythematosus, it would have been interesting
to try out this strategy in patients with schizophrenia. However,
caution is warranted, as the cytokine antagonists have a range
of adverse effects due to the multiple and pleiotropic functions
of the cytokines (121). According to Baker and Isaacs (18),
the novel biological drugs with immune-modulating properties
can be described according to their target of action: (1) drugs
directed toward activity in the T-helper 17 immune axis: drugs
directed toward IL-23p19, IL-17, or IL-12/23p40, (2) drugs active
against type I and II Interferons, (3) drugs interfering in the
lymphocyte recruitment by intervening in the adhesion process
either by sphingosine−1-phosphate receptor inhibition or by
integrin blockade, (4) Janus kinase inhibitors—first generation
and second generation selective inhibitors, (5) drugs targeting
B cells, (6) drugs modulating T cell function, and (7) bispecific
antibodies.
Two studies on the effect of novel biologicals in patients
with schizophrenia have been published, both with tocilizumab
which is a humanized IL-6 receptor monoclonal antibody.
Tocilizumab was tried in an open label study (107), and 2017
an RCT of 36 patients with residual symptoms of schizophrenia
was published (17). In the study by Miller et al. (107), 6
participants (4 with schizophrenia and 2 with schizoaffective
disorder) entered and 5 completed an 8 week open trial of
adjunctive injections with 4 mg/kg tocilizumab at baseline and
after 4 weeks, with the aim of studying the effect on cognition.
All subjects improved in a processing speed measure, and 5
out of 6 improved also on a global cognition measure. The
authors state that the signal-to-noise ratio may be increased in
future studies if only patients with baseline inflammation were
included, which was not the case in this study. Girgis et al.
(17) reported a study where 36 clinically stable individuals with
schizophrenia and PANSS total scores >60 were randomized to
treatment with 3 monthly injections with 8 mg/kg tocilizumab
or placebo at baseline and after 4 weeks. The results showed
no effect of tocilizumab on any behavioral outcome, while
CRP decreased and IL-6 and IL-8 increased. No prediction of
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TABLE 1 | Drug treatment of inflammation and immune dysregulation in schizophrenia.
Drugs Level of evidence Effect on primary outcome Effect on secondary outcome
ANTI-INFLAMMATORY DRUGS
NSAIDs
Aspirin/acetyl-salicylic acid Meta-analyses (16, 105) ↓PANSS total (16) No effects in cognitive testsc






Prednisolone Protocols for RCTs publisheda
NOVEL BIOLOGICALS—MONOCLONAL ANTIBODIES AGAINST CYTOKINES/CYTOKINE RECEPTORS/CELL ADHESION MOLECULES
Tocilizumab One RCT in patients with residual symptoms (17) No effect at week 12 on the
PANSS total
No effects on the MATRICS,
PANSS subscales, CGI, GAF,
↓CRP, ↑IL-6, and IL-8
One open study (107) ↑BACS. No significant changes in psychopathology scores, cytokines or CRP
Protocol for RCT publisheda
Siltuximab Protocol for RCT publisheda
Natalizumab Protocol for RCT publisheda
MISCELLANEOUS DRUGS WITH ANTI-INFLAMMATORY ACTIONb
N-acetylcysteine Meta-analyses (16, 108) ↓Total psychopathology (SMD =
−0.74).
No effect on PANSS subscales
(108)
No difference in any cause
discontinuation rate or adverse
drug reactions





No effect on other cognitive
tests, psychopathology, or MRI
brain volumes
Pioglitazone One RCT (110) ↓PANSS negative ↓PANSS total.
No difference in PANSS positive,
HDRS
Simvastatin One RCT (111) ↓PANSS negative ↓PANSS total. No difference
PANSS positive or general
psychopathology
Pravastatin One RCT (112) ↓LDL cholesterol. No effect on
CRP, PANSS total score,
MATRICS over 12 weeks
↓PANSS positive at 6 weeks
Minocycline Meta-analyses (113, 114) ↓PANSS total (113, 114) ↓PANSS positive (113), negative
(113, 114), and general
psychopathology (113, 114)
subscales
Two recent RCTs (115, 116) No effect on PANSS total (115) or
PANSS negative subscale (116)





bNegative trials or drugs with negative findings in updated meta-analyses are not included.
cAssessed only in one study (27).
dThe inclusion criteria included an RBANS score < 1 SD below mean.
NSAIDS, non-steroidal anti-inflammatory drugs; PANSS, Positive andNegative Syndrome Scale; RCT, randomized controlled trial; CGI, Clinical global impression; GAF, Global assessment
of functioning; CRP, C-reactive protein; IL, interleukin; BACS, The Brief Assessment of Cognition in Schizophrenia; SMD, standardized mean difference; RBANS, Repeatable Battery for
the Assessment of Neuropsychological Status; WCST, Wisconsin Card Sorting Test; MRI, Magnetic resonance imaging; LDL, low density lipoprotein.
outcome was seen by baseline CRP or the measured cytokines.
No selection procedure based on elevated baseline inflammation
measures was implemented, and the authors underlined the
possibility that enriching the sample with inclusion of only
individuals with an elevated CRP could have influenced the
results.
We have not been able to identify other completed studies
with novel biologicals targeting cytokines or cytokine receptors
in schizophrenia. However, at the clinicaltrials.gov website
three trials currently recruiting participants are listed, two
from Augusta and one in London. One study conducted by
the group of Brian Miller at Augusta University in Georgia,
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plans to randomize 30 stable outpatients with schizophrenia or
schizoaffective disorder with CRP >5 mg/L to adjunct treatment
with siltuximab which is a recombinant IL-6 monoclonal
antibody, or placebo. In another study by the same group 20
stable outpatients with CRP >5 mg/L will be randomized to
receive treatment with tocilizumab or placebo for 12 weeks.
Lastly, a study conducted by Tiago Marques and Oliver Howes,
Institute of Psychiatry at Kings college in London, plans to
randomize 60 individuals with FES or other psychotic disorder to
treatment with natalizumab, which is a humanized monoclonal
antibody against the cell adhesion molecule α4-integrin, or
placebo. The results are integrated in Table 1.
Miscellaneous Drugs With
Anti-inflammatory Actions
N-acetylcysteine (NAC) is a drug with several established
indications, including the treatment of paracetamol intoxication.
NAC interacts with a wide range of physiological pathways,
and has anti-oxidative and anti-inflammatory effects (122). A
recent systematic review and meta-analysis summarizing the
results from 3 RCTs with schizophrenia patients found that
NAC improved total psychopathology (108). A recent RCT
including 63 early psychosis patients found that NAC had no
effects on positive and negative symptoms or functional outcome,
but a significant effect on processing speed (123). Interestingly,
patients with higher values of glutathione peroxidase activity
in blood cells (GPxBC), an indicator of oxidative stress and
associated with brain glutathione levels, improved significantly
on positive symptoms, leading the authors to suggest that GPxBC,
could be a theranostic marker for NAC treatment (123).
Erythropoetin (EPO) is a glycoprotein secreted by the
kidney in response to hypoxia that stimulates bone-marrow
erythropoiesis. EPO also has an anti-inflammatory effect in
the brain by modulating microglia responses and decreasing
BBB hyperpermeability (124), among a wide range of other
pharmacological actions. Recombinant EPO is used as a drug to
treat anemia associated with kidney failure and cancer therapy,
and has also been tried to improve cognition in patients with
schizophrenia. A systematic review with a quantitative synthesis
included 78 animal and human studies (125), including only
one double-blind RCT (109). The results of this 3 month study
showed that the patients with schizophrenia improved on all
cognitive tests, but no improvement on the PANSS scores was
found, and the authors suggest a role for EPO as an add-
on treatment to antipsychotic drugs for patients with cognitive
dysfunction. However, serious concerns regarding for example
vascular side effects may limit the clinical use of EPO (125).
Statins have been tried in RCTs as add-ons to treatment
with antipsychotics for patients with schizophrenia. Simvastatin
showed effect on negative symptoms in an RCT with 66 patients
randomized to simvastatin vs. placebo (111). According to the
registrations on clinicaltrials (https://clinicaltrials.gov/), there are
at least two on-going studies with simvastatin, one also with a
published protocol (126). Vincenzi et al. randomized 60 patients
with schizophrenia or schizoaffective disorder to pravastatine
or placebo (112). Pravastatine significantly reduced PANSS total
score from baseline to 6 weeks, but not at 12 weeks. Cholesterol
and low density lipoprotein were reduced. In the subgroup with
CRP above 2 mg/L cognitive measures were improved between
baseline and 6 weeks.
Pioglitazone is an anti-diabetic drug also demonstrated
to inhibit inflammatory pathways (127). Iranpour et al.
randomized 40 patients with negative symptoms to pioglitazone
vs. placebo as add-on to risperidone treatment and found
significant decrease in negative symptoms after 8 weeks
treatment (110).
Estrogens also have anti-inflammatory actions (128). The
meta-analysis by Sommer et al. (16) included 8 studies, and
concluded that treatment with estrogens have a significant effect
on the PANSS total score. The same meta-analysis also included
studies with davunetide (n = 2), fatty acids EPA/DHA(n = 7),
and minocycline(n= 4). However, noen of these drugs showed a
significant effect on the PANSS total score.
Minocycline is a second generation tetracycline with
anti-inflammatory properties (129) and a potential for
neuroprotective use for example after stroke (130). It has
been tried for improving symptoms in schizophrenia in
several studies, and the results summarized in meta-analyses
(16, 113, 114). Solmi et al. (114) performed a systematic review
and meta-analysis of studies published up to February 2016
and identified six RCTs with 215 participants randomized to
minocycline and 198 to placebo. Minocyline was superior to
placebo for PANSS total score, and the negative and general
PANSS subscale, the conclusion was in contrast to the earlier
meta-analysis by Sommer et al. (16) that included three studies
with high heterogeneity. Xiang et al. (113) published a meta-
analysis summarizing published RCTs upto January 2016 and
included eight RCTs with 286 participants on minocycline and
262 on placebo. Also in this meta-analysis minocycline was
superior to placebo in improving PANSS total, negative and
general subscale, and here also for the positive subscale. However,
two new RCTs do not find an effect of minocycline vs. placebo
(115, 116). Deakin et al. (116) randomized 207 people with
schizophrenia-spectrum disorder with an illness duration <5
years to minocycline or placebo, half and half. No effect on the
primary outcome PANSS negative subscale or other symptoms
of schizophrenia was identified after 12 months treatment.
Weiser et al. (115) randomized 200 people with schizophrenia or
schizoaffective disorder to 16 weeks treatment with minocycline
or placebo as add-on to antipsychotic treatment. No effects on
the primary outcome PANSS total or the secondary outcomes
PANSS subscales, Clinical Global Impression Scale–Severity
or–improvement scales, Brief Assessment of Cognition in
Schizophrenia and drop out rates were identified. Thus, after
these two negative, but rather large and well performed RCTs
the status of minocycline as an agent to treat patients with
schizophrenia is rather cloudy. However, and related to the
main aim of this paper, the trials did not enrich their sample
for patients with elevated measures of inflammation. It can not
be ruled out that the negative and contrasting findings in the
minocycline literature are caused by applying the minocycline to
an unselected sample (131). Also the results for miscellaneous
drugs are summarized in Table 1.
Frontiers in Psychiatry | www.frontiersin.org 11 January 2019 | Volume 9 | Article 753
Kroken et al. Constructing the Immune Signature of Schizophrenia
Theranostic Biomarkers in Studies With
Anti-inflammatory/Immune-modulating
Drugs for Patients With Schizophrenia
In summary, we did not find any completed studies on anti-
inflammatory treatment or immune-modulating drugs that have
selected patients based on elevated markers of inflammation.
A few studies have analyzed subgroups of participants with
for example elevated CRP, and indications of more beneficial
effects of anti-inflammatory treatment in subgroups with raised
CRP have been identified. However, this applies only to a
minority of studies, and it is conceivable that the influence
of anti-inflammatory treatment could have been stronger if
the treatment were targeted to participants with elevated
markers of inflammation. Several protocols for ongoing add-
on trials have been published at clinicaltrials.gov/ and a few
of these seem to plan selection of participants based on an
elevated CRP level. If this strategy is successful, CRP could
be regarded as a first theranostic biomarker for tailoring anti-
inflammatory/immune-modulating treatment to patients with
schizophrenia, which could pave a way for more sophisticated
markers in the future. An interesting clustering of well-known
and putative immune-modulating drugs based on the in-vitro
influence on cytokine levels were done by Wallner et al. (132).
They identified cyclosporine A and tacrolimus among other
drugs as one group predominately influencing IFN-gamma, IL-
2 and IL-17, while the JAK family of drugs inhibits IFN-γ
and increases IL-2 and the chemokine MIP3-α. Consequently,
if a specific immune/inflammation activation pattern can be
repeatedly identified in patients with schizophrenia, a more
specific and hopefully more effective immune-modulating drug
therapy can be explored in future trials.
CONSTRUCTING THE INFLAMMATORY
SIGNATURE OF SCHIZOPHRENIA FOR
CLINICAL AND RESEARCH PURPOSE
The search for theranostic biomarkers for anti-inflammatory
or immune-modulating treatment is still in its infancy. When
selectively reviewing how inflammation and immunological
dysregulation can be assessed in order to diagnose low-grade
inflammation in patients with schizophrenia, two main issues
need to be addressed. Firstly, the research conducted so far
regarding immune dysregulation in schizophrenia has been
focused to a large extent on finding differences on a group level
comparing patients with schizophrenia and healthy controls,
rather than determining the level of inflammation in the
individual patient. Many advanced methods and bioinformatical
tools are increasingly available and will doubtless be further
developed to uncover cell populations or molecules that could
serve as theranostic biomarkers and help assess the chances
that anti-inflammatory or immune-modulating treatment will
be of help to the individual patient. Secondly, although studies
with proteomics, metabolomics and brain imaging offer exciting
possibilities, presently the less sophisticated option of measuring
the protein level of CRP and pro-inflammatory cytokines—
IL-1β, IL-6, TNF-α, TGF-β–in serum is far more convenient
for identifying patients with low-grade inflammation. Among
the pro-inflammatory cytokines, IL-6 is found most often to
be elevated in patients with schizophrenia (3), and has also
been suggested as a possible state marker for acute relapse (2).
However, as IL-6 seems to be both pro- and anti-inflammatory,
more research is needed to establish the usefulness of IL-6
as a biomarker in schizophrenia (39). The general problem
of assaying cytokines reliably and standardized remains and
constrains further development of the field. Furthermore, and as
discussed by Goldsmith et al. (53), it would be useful to agree
internationally on a panel of cytokine network components to be
studied in order to increase comparability between studies, and
also to evaluate patterns of cytokines for example with cytokine
ratios instead of focusing on individual cytokines.
There is some evidence indicating a link between peripheral
levels of inflammation and symptom severity. For instance, CRP
levels correlates with positive symptoms, negative symptoms,
and cognitive dysfunction (60) and a level of CRP >3.8
mg/L increased the chance of therapeutic response to anti-
inflammatory treatment with aspirin in one study (118). Besides
this unique study, the literature offers little guidance as to the
use of inflammatory parameters as theranostic biomarkers. In
the current protocols for two ongoing studies with monoclonal
antibodies conducted by dr. Brian Miller at Augusta University,
the CRP level of 5 mg/L is chosen. In another study with add-
on prednisolone, sponsored by Erik Johnsen at the Unversity
of Bergen, a CRP level of >3.8 mg/L is chosen as an inclusion
criterion (clinicaltrials.gov), based on the study by Weiser et al.
(118). Adding to this, and based on the in-vitro findings of
Wallner et al. (132), specific drugs could probably use specific
measures to show response of treatment. We are certain that
drug trials with anti-inflammatory or immune-modulating drugs
would benefit from an concenting scientific community on how
to select participants. This would increase comparability and
also the possibility to show effect. Another important aspect
calling for international collaborations is the need to increase
the number of participants in drug trials in order to explore
the fascinating possibility of disease-modifying treatment for
schizophrenia posed by immune-modulating drugs.
Moreover, it seems clear that inflammation in this context
should be regarded more as a dimension rather than a category.
Thus, determining the degree of inflammation that causes or
contributes to increased symptoms or deteriorating function is
essential in the development of novel theranostic biomarkers
(133). This can only be done in large longitudinal studies where
multiple markers are monitored and predictors for increased
symptoms, decreased function and other adverse developments
are identified. Currently, biomarker panels are preferred to single
markers (86), and individual differences must be accounted
for (11).
SUMMARY
• The existing knowledge does not provide evidence to
conclude that all patients with schizophrenia have increased
inflammation, on the contrary; most studies report a low-
grade inflammation in a subset of around 35–50% of patients
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with schizophrenia, and in the transition from descriptives on
a group level to individual diagnosis the best way to diagnose
inflammation in schizophrenia must be defined
• CRP and the pro-inflammatory cytokines are the proteins
that at present should be further validated as biomarkers for
inflammation in schizophrenia. Furthermore, they correlate
at least in some studies with symptoms and phases of illness,
and measurement is standardized and available from clinical
laboratories
• More methods have the potential to develop biomarkers for
inflammation in schizophrenia: immune cell characteristics
measured by flow cytometry, proteins measured by
proteomic methods, or other molecular elements mapped by
metabolomics.
• The ultimal goal would be a panel of molecules with proven
specificity and sensitivity as theranostic biomarkers which
could be supported by brain imaging methods—to select
patients for anti-inflammatory or immune-modulating
treatment. Large longitudinal studies following standard
development for biomarkers are needed to fulfill
this goal.
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